Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: RT who wrote (8932)	6/2/1998 7:30:00 PM
From: DaiS	Respond to of 23519

RT, For the gene therapy I would not be surprised if Vivus are working on antisense technology or some related approach. Anti-message for PDE5 is is incorporated into the muse pellet, taken up by the penis, binds to message (mRNA) for PDE5 thus preventing the synthesis of this enzyme. Perfect local delivery route. If it worked would put viagra out of business in one day. DaiS

To: RT who wrote (8932)	6/2/1998 8:21:00 PM
From: VLAD	Respond to of 23519

RT, The press release quotes the CFO as saying that Vivus is working on developing other treatments for ED including an oral pill. It also mentions Vivus developing treatments for incontinance and sexual dysfunctions including premature ejaculation. If Vivus announces some sort of cooperative agreement between themselves and say J&J or Astra to develop this oral ED pill before June's option expiration then we will all know the meaning behind the large open interest on the June 30 and June 40 calls.